"uuid:ID","rationale","instanceType","id","versionIdentifier"
"c66d5681-c38d-4121-97d7-c698a848a65c","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","StudyVersion_1","2"
